Factors influencing dopaminergic therapy of Parkinson's disease.
Horowski
R
R
Schering AG, Clinical Research, Berlin, FRG.
D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
D015259:Dopamine Agents; D007980:Levodopa; D004298:Dopamine